spironolactone has been researched along with Depressive Disorder, Treatment-Resistant in 1 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Depressive Disorder, Treatment-Resistant: Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies. (Campbell's Psychiatric Dictionary, 9th ed.)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Juruena, MF | 1 |
Pariante, CM | 1 |
Papadopoulos, AS | 1 |
Poon, L | 1 |
Lightman, S | 1 |
Cleare, AJ | 1 |
1 trial available for spironolactone and Depressive Disorder, Treatment-Resistant
Article | Year |
---|---|
The role of mineralocorticoid receptor function in treatment-resistant depression.
Topics: Canrenone; Case-Control Studies; Depressive Disorder, Treatment-Resistant; Female; Humans; Hydrocort | 2013 |